文献速递神经免疫帕金森病与运动障碍

RIMKLA-IgG副肿瘤性神经综合征伴小脑性共济失调的鉴定

Identification of RIMKLA-IgG Paraneoplastic Neurological Syndrome With Cerebellar Ataxia.
PubMed 文献 · JAMA Neurol · 2026-11-09

这项多中心病例系列研究在2015至2020年间筛查了35例疑似自身免疫性神经系统疾病患者,其中8例检出靶向细胞内神经蛋白RIMKLA的IgG抗体,多数(6/8)合并小细胞肺癌,临床表现为进行性小脑性共济失调、复视、第VI脑神经麻痹及感觉运动异常。RIMKLA-IgG被确定为一种新的副肿瘤性神经综合征诊断生物标志物。

要点

  • 8例患者检出RIMKLA-IgG抗体,中位年龄65岁,男性6例(75%)。
  • 6/8例(75%)合并小细胞肺癌,所有患者脑脊液呈炎性改变并伴免疫球蛋白合成。
  • 临床以进行性小脑性共济失调、复视、第VI脑神经麻痹及感觉运动异常为特征。

核心结论

  • RIMKLA-IgG是一种新的细胞内抗原副肿瘤性神经综合征生物标志物,与小脑及后脑脑炎相关,可能累及周围神经和运动通路。

研究设计与样本

  • 多中心病例系列研究,纳入2015至2020年加州大学旧金山分校(UCSF)收集的未明确中枢神经系统疾病患者样本,并在法国副肿瘤性神经综合征(PNS)与自身免疫性脑炎(AE)参考中心通过盲法细胞法和组织法检测进一步筛查患者。

主要发现

  • 共转诊35例患者,鉴定出8例(中位[IQR]年龄65[47-74]岁;男性6例[75%])存在靶向细胞内神经蛋白核糖体修饰蛋白RimK样家族成员A(RIMKLA)的IgG。
  • 首例UCSF指示患者合并小细胞肺癌和炎性小脑性共济失调,其脑脊液在小脑和脑干深部核团显示特异性染色模式,但所有已知PNS生物标志物检测均为血清阴性。
  • 后续筛查发现7例具有相似临床特征的患者,表现为进行性小脑性共济失调、复视、第VI脑神经麻痹及感觉和运动异常。
  • 多数患者(6/8[75%])合并小细胞肺癌,所有患者均显示炎性脑脊液和免疫球蛋白合成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autoimmune cerebellar ataxias are debilitating neurological syndromes that need early detection and intervention. Antineural antibodies are a crucial diagnostic marker, however, lack of knowledge of specific autoantibodies in seronegative patients remains a significant challenge. OBJECTIVE: To pair a cutting-edge, standardized, and rigorous autoantibody detection pathway with global clinical networks to identify novel autoantibody markers of autoimmune ataxia. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter case series study that included samples of patients with uncharacterized central nervous system disorders, collected between 2015 and 2020 at the University of California, San Francisco (UCSF). A comprehensive screening for additional patients was conducted using a blinded cell-based and tissue-based assay in the French reference center on paraneoplastic neurological syndrome (PNS) and autoimmune encephalitis (AE). Analysis was completed in 2026. Referred participants included those with idiopathic neurological disease with suspicion of autoimmune etiology, controls with noninflammatory disease, and patients with known paraneoplastic autoantibody associations who served as positive controls. Sera and cerebrospinal fluid were collected for autoantibody screening and validation experiments. EXPOSURES: Autoantibody screening and candidate antibody validations. MAIN OUTCOMES AND MEASURES: Detection of autoantibodies and characterization of their usefulness as biomarkers of autoimmune clinical symptoms. RESULTS: A total of 35 patients were referred, and 8 patients (median [IQR] age, 65 [47-74] years; 6 male [75%]) were identified to have IgG targeting the intracellular neural protein ribosomal modification protein RimK-like family member A (RIMKLA). Initially, cerebrospinal fluid (CSF) from a UCSF index patient with small cell lung cancer and inflammatory cerebellar ataxia showed a specific staining pattern in the deep nuclei of the cerebellum and brainstem but was seronegative on all known panels of PNS biomarkers. Subsequent screening identified 7 additional patients sharing a similar clinical profile characterized by progressive cerebellar ataxia, diplopia, cranial VI paresis, and sensory and motor abnormalities. The majority of patients (6 of 8 [75%]) had associated small cell lung cancer. All patients also exhibited inflammatory CSF and immunoglobulin synthesis. CONCLUSIONS AND RELEVANCE: In this case series, novel PNS autoantibodies targeting the neural protein RIMKLA were identified in patients with small cell lung cancer and cerebellar ataxia. RIMKLA-IgG represents a new diagnostic biomarker for an intracellular-antigen PNS associated with cerebellar and hindbrain encephalitis with possible peripheral and motor involvement.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Mandel-Brehm C, Witek N, Kung AF, et al. Identification of RIMKLA-IgG Paraneoplastic Neurological Syndrome With Cerebellar Ataxia. JAMA Neurol. 2026. PMID: 43002412. doi:10.1001/jamaneurol.2026.4017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。